結節性癢疹治療市場（按產品、通路和地區劃分）2024 年至 2031 年

結節性癢疹治療市場評估 - 2024 - 2031

由於結節性癢疹 (PN) 盛行率不斷上升以及醫療專業人員和患者意識的提高，結節性癢疹 (PN) 治療市場正在發展。結節性癢疹是一種持續性皮膚病，會引起搔癢性結節並嚴重影響患者的生活品質。過去十年，由於診斷程序的改進以及皮膚科醫生和全科醫生對該疾病的認識的提高，確診病例數不斷增加，預計到 2024 年該市場的銷售額將超過 13 億美元，到 2031 年估值將達到約 19 億美元。

遠距醫療和數位健康平台的日益普及使得皮膚科諮詢和治療變得更加容易，從而促進了 PN 治療的需求不斷增長。因此，由於患病率上升、治療方法改善以及患者獲得醫療服務的管道改善等多種因素，PN 治療市場預計將大幅增長，預計 2024 年至 2031 年期間的複合年增長率為 5.30%。

結節性癢疹治療市場定義/概述

結節性癢疹 (PN) 是一種慢性皮膚病，其特徵是由於持續抓撓和發炎而導致頻繁出現高度刺激性的結節。結節性癢疹的治療重點在於緩解症狀、控制搔癢和解決根本原因，以改善患者的生活品質。局部治療是治療結節性癢疹最常見的方法之一。皮質類固醇、鈣調神經磷酸酶抑制劑和辣椒素洗劑常用於治療發炎和搔癢。

結節性癢疹 (PN) 是一種持續性皮膚病，會引起搔癢性結節並嚴重影響患者的生活品質。結節性癢疹的治療方法多種多樣，主要集中在症狀管理、緩解搔癢和改善皮膚病變。局部治療是治療結節性癢疹最常見的適應症之一。這些包括皮質類固醇、鈣調神經磷酸酶抑制劑和辣椒素乳膏。

PN 管理的未來可能需要結合藥物學和非藥物學技術的綜合方法。隨著有關 PN 心理影響的文獻越來越多，包括行為療法、壓力管理和生活方式改變在內的綜合治療策略正變得越來越被廣泛接受。

辣椒素霜需求的增加會影響產品細分市場嗎？

對辣椒素乳膏的需求不斷增加是結節性癢疹治療市場的主要驅動力，尤其是在產品領域。辣椒素是從辣椒中提取出來的，有望用於治療結節性癢疹引起的劇烈瘙癢。結節性癢疹的盛行率不斷上升是推動這項需求的主要原因。根據美國皮膚病學會雜誌發表的一項研究，美國結節性癢疹的盛行率估計為每十萬人中有72例。這意味著僅在美國就有大約 23 萬人患有這種疾病。根據國家濕疹協會的數據，PN 影響著普通社區中每 4,000 人中的 1 人，顯示其流行範圍十分廣泛。

根據美國國家生物技術資訊中心 (NCBI) 的數據，在臨床試驗中，33% 使用辣椒素乳膏的患者報告瘙癢症狀明顯減少，而使用安慰劑的患者只有 7%。這表明辣椒素可能有助於治療 PN 症狀。此外，人們對天然和非處方藥物的興趣日益濃厚，這也推動了辣椒素乳膏市場的發展。美國皮膚病學會指出，外用辣椒素無需處方即可獲得，這對許多人來說是一種可行的選擇。

合格醫療保健專業人員的短缺是否會阻礙結節性癢疹治療市場的發展？

結節性癢疹治療市場可能會因熟練醫療保健人員的短缺而受到阻礙，儘管各種因素可能會減輕這一潛在障礙。一個主要的促成因素是全球結節性癢疹（PN）的盛行率不斷增加。儘管由於診斷不足，確切數字有限，但研究表明，在美國每 10 萬人中約有 72 人患有 PN。頻率的增加促使對治療方案和專家的需求增加。此外，診斷方法的進步使得識別 PN 患者變得更加容易。例如，2022 年《美國皮膚病學會雜誌》上發表的一項研究發現，與單純的臨床檢測相比，皮膚鏡檢查使 PN 診斷的準確率提高了 23%。

預計這一巨大的經濟影響將刺激對治療開發和專業培訓的投資。此外，FDA 於 2022 年批准 dupilumab 用於治療 PN，這也增加了人們對該市場領域的認識和興趣。據美國國家濕疹協會稱，dupilumab 在臨床試驗中將搔癢強度降低了 60%，並有可能改善許多 PN 患者的生活品質。儘管醫療人才短缺仍然是一個問題，但有幾個市場因素可能有助於抵消其影響。儘管面臨勞動力課題，但疾病意識的提高、經濟激勵和治療方法的改善應該會吸引更多的專家進入該領域，並有助於推動市場擴張。然而，要充分發揮市場的潛力，必須解決醫療人才短缺的問題。

目錄

第 1 章 全球結節性癢疹治療市場簡介

• 市場概況
• 研究範圍
• 先決條件

第 2 章執行摘要

第 3 章：經過驗證的市場研究方法

• 資料探勘
• 驗證
• 主要來源
• 資料來源列表

第 4 章全球結節性癢疹治療市場展望

• 概述
• 市場動態
  • 驅動程式
  • 阻礙因素
  • 機會
• 波特五力模型
• 價值鏈分析

第5章全球結節性癢疹治療市場（按產品）

• 概述
• 抗組織胺藥
• 辣椒素霜
• 皮質類固醇
• 潤膚劑
• 其他

第6章全球結節性癢疹治療市場（依通路）

• 概述
• 零售藥局
• 醫院藥房
• 網路藥局

第7章全球結節性癢疹治療市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
  亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區
  • 拉丁美洲
  • 中東和非洲

第 8 章 全球結節性癢疹治療市場的競爭格局

• 概述
• 各公司的市場排名
• 主要發展策略

第9章 公司簡介

• Bayer AG
• Galderma SA（Nestle Skin Health Company）
• Pfizer, Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline Plc
• VYNE Therapeutics, Inc.
• Trevi Therapeutics, Inc
• Merck & Co., Inc.
• Novartis AG
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson

第10章 附錄

• 相關報告

Prurigo Nodularis Treatment Market Valuation - 2024-2031

The Prurigo Nodularis (PN) therapy market is developing in response to the condition's increasing prevalence and rising awareness among healthcare practitioners and patients. Prurigo nodularis is a persistent skin illness that causes itchy nodules and has a major impact on a patient's quality of life. Over the last decade, there has been an increase in the number of diagnosed cases, partially due to improved diagnostic procedures and increased recognition of the disorder by dermatologists and general practitioners by enabling the market to surpass a revenue of USD 1.30 Billion valued in 2024 and reach a valuation of around USD 1.90 Billion by 2031.

The increasing use of telemedicine and digital health platforms makes dermatological consultations and treatments more accessible which contributes to the growing demand for PN therapies. As a result, the PN treatment market is predicted to expand significantly driven by a combination of rising illness prevalence, therapeutic improvements, and improved patient access to healthcare services by enabling the market to grow at a CAGR of 5.30% from 2024 to 2031.

Prurigo Nodularis Treatment Market: Definition/ Overview

Prurigo nodularis (PN) is a chronic skin disorder distinguished by very irritating nodules that are frequently caused by persistent scratching and inflammation. Prurigo nodularis treatment focuses on symptom relief, itch management, and addressing underlying causes to enhance the patient's quality of life. Topical therapies are one of the most common methods for treating PN. Corticosteroids, calcineurin inhibitors, and capsaicin lotions are frequently used to treat inflammation and itching.

Prurigo nodularis (PN) is a persistent skin ailment that causes itchy nodules and has a major influence on a patient's quality of life. Prurigo nodularis is treated using a variety of techniques focused on symptom management, itch relief, and skin lesion improvement. Topical therapies are one of the most common applications for PN therapy. These include corticosteroids, calcineurin inhibitors, and capsaicin creams.

The future of PN management will most likely involve an integrated approach that combines pharmacological and non-pharmacological techniques. As more is learned about the psychological impact of PN, comprehensive treatment strategies that include behavioral therapy, stress management, and lifestyle changes are becoming more widely accepted.

Will Increasing Demand for Capsaicin Cream Influence the Product Segment?

The growing demand for capsaicin cream is a major driver in the prurigo nodularis treatment market, particularly within the product segment. Capsaicin, derived from chili peppers has shown promise in treating the severe itching associated with prurigo nodularis. The increasing prevalence of prurigo nodularis is a major driver of this demand. According to research published in the Journal of the American Academy of Dermatology, the estimated prevalence of PN in the United States is 72 instances per 100,000 individuals. This equates to roughly 230,000 people impacted by this illness in the United States alone. According to the National Eczema Association, PN affects around one in every 4,000 people in the general community demonstrating its widespread prevalence.

According to the National Center for Biotechnology Information (NCBI) in a clinical trial, 33% of patients receiving capsaicin cream reported a significant reduction in pruritus compared to only 7% in the placebo group. This illustrates capsaicin's potential usefulness in treating PN symptoms. Furthermore, the growing interest in natural and over-the-counter medicines is driving up the market for capsaicin cream. The American Academy of Dermatology points out that topical capsaicin is available without a prescription making it a viable alternative for many people.

Will Lack of Qualified Healthcare Professionals Hamper the Prurigo Nodularis Treatment Market?

The prurigo nodularis treatment market may be hampered by a lack of skilled healthcare practitioners, however, various factors may mitigate this potential barrier. One major factor is the rising global prevalence of prurigo nodularis (PN). While exact numbers are limited due to underdiagnosis, research indicates that PN affects roughly 72 per 100,000 persons in the United States. The increased frequency necessitates a greater demand for treatment choices and professionals. Furthermore, advances in diagnostic procedures are enhancing the detection of PN patients. For example, a 2022 study published in the Journal of the American Academy of Dermatology discovered that dermoscopy improved diagnostic accuracy for PN by 23% when compared to clinical examination alone.

This significant economic impact is expected to drive investment in treatment development and specialized training. Furthermore, the FDA's approval of dupilumab for PN therapy in 2022 has raised awareness and interest in this market area. According to the National Eczema Association, dupilumab showed a 60% reduction in itch severity in clinical studies, potentially enhancing the quality of life for many PN sufferers. While the scarcity of healthcare personnel remains a worry, several market factors may assist in offsetting its effects. Despite labor issues, increasing disease awareness, economic incentives, and treatment improvements should attract more specialists to the sector and drive market expansion. However, addressing the healthcare personnel deficit is critical to fully fulfilling the market's potential.

Category-Wise Acumens

Will Widespread Use and Trust in Corticosteroids Influence the Product Segment?

Corticosteroids dominate the market owing to their demonstrated usefulness in regulating inflammation and lowering itching caused by the illness. Dermatologists frequently prescribe corticosteroids as the first line of treatment. They are available in topical, oral, and injectable forms. They operate by inhibiting the immunological response that causes itchy nodules resulting in great alleviation for patients. Topical corticosteroids are especially popular because they may be applied directly to the afflicted areas providing localized treatment with less systemic adverse effects than oral or injectable alternatives. Corticosteroids' broad use and trust supported by multiple clinical research and decades of medical practice solidifies their dominance in the PN therapy market.

Corticosteroids' dominance in the PN therapy market is driven not only by their efficacy but also by their availability. These drugs are readily available and come in a variety of dosages and formulations making them appropriate for different stages and severity levels of PN. This flexibility enables healthcare providers to adjust treatment strategies to particular patient demands, hence improving treatment outcomes. Furthermore, corticosteroids are frequently covered by insurance programs which reduces patients' financial burden and encourages treatment adherence.

Will the Rising Preference for Medications Drive Growth in the Distribution Channel Segment?

The retail pharmacies category is expected to have the highest compound annual growth rate (CAGR) in the prurigo nodularis treatment market over the forecast period. This dominance is partly due to an increasing propensity for obtaining pharmaceuticals from retail pharmacies which is heavily affected by their accessibility and convenience. Retail pharmacies are frequently more accessible to patients than hospitals or online pharmacies as they have longer hours and are placed in convenient neighborhood locations. This makes them the first choice for many people who need fast relief from the symptoms of prurigo nodularis which can be quite uncomfortable and debilitating.

Retail pharmacies frequently offer numerous incentives to attract patients such as discounts and loyalty programs. These cost-cutting approaches are especially tempting to patients who need long-term treatment for chronic illnesses such as prurigo nodularis. The economic benefits provided by retail pharmacies can greatly lessen patient's financial burden encouraging them to continue their therapy uninterrupted. This is especially critical in the treatment of prurigo nodularis where strict adherence to prescribed medication regimens is required for successful symptom control and flare-up avoidance.

Country/Region-wise Acumens

Will the Rising Disease Awareness Drive the Growth in the Asia Pacific Region?

The Asia Pacific region is expected to see considerable growth in the Prurigo Nodularis (PN) treatment market owing to increase in illness awareness and improved healthcare infrastructure. As more people and healthcare providers become aware of the signs and effects of PN, there is a greater desire for effective treatments. According to research published in the Journal of the American Academy of Dermatology, the frequency of PN in Asia varies between 0.1% and 3.8% of the population depending on the country and demography. This incidence combined with the massive population bases in countries such as China and India indicates a significant potential market for PN treatments.

Organizations such as the International Forum for the Study of Itch (IFSI) and the Asian Academy of Dermatology and Venereology (AADV) have played an important role in educating both patients and healthcare professionals about PN contributing to the increase in disease awareness. According to World Health Organization (WHO) research, dermatological disorders including PN are becoming more widely recognized as serious health concerns in the Asia Pacific region with a 15% increase in reported cases in the last five years.

Will the Rising Healthcare Expenditures and a Growing Patient Population Boost the Market in the North American Region?

The prurigo nodularis (PN) treatment market in North America is expected to increase significantly owing to many main factors. One of the main drivers is the region's increase in healthcare expenses. According to the Centers for Medicare and Medicaid Services (CMS), U.S. healthcare spending will exceed USD 4.3 Trillion in 2021, up 2.7% from 2020. This trend of increase in healthcare spending is anticipated to continue with forecasts indicating that it would reach USD 6.2 Trillion by 2028. The significant investment in healthcare infrastructure and research creates an enabling environment for the development and implementation of novel PN treatments. Furthermore, the expanding patient population is a key driver of market expansion.

Another key cause is the growing awareness and diagnosis of PN. The National Eczema Association has been actively striving to increase awareness of PN and other associated disorders resulting in better recognition and diagnosis. This, together with developments in diagnostic procedures is expected to enhance the identified patient pool accelerating market expansion. The market also benefits from ongoing R&D initiatives. The National Institutes of Health (NIH) has financed various research on PN, and clinicaltrials.gov lists more than 20 active or recruiting clinical trials for PN treatments as of 2024. This extensive pipeline of prospective therapies is projected to provide more effective treatment alternatives, hence supporting market growth.

Competitive Landscape

The prurigo nodularis treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the prurigo nodularis treatment market include:

Bayer AG

Galderma SA (Nestle Skin Health Company)

Pfizer, Inc.

Sanofi SA

Takeda Pharmaceutical Company Limited

GlaxoSmithKline Plc

VYNE Therapeutics, Inc.

Trevi Therapeutics, Inc

Merck & Co., Inc.

Novartis AG

Celgene Corporation

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Latest Developments

In February 2023, Pfizer is planning an unprecedented number of pharmaceutical launches with the corporation expected to release 19 new drugs over the next 18 months.

In June 2023, Novartis announced that it has agreed to acquire Chinook Therapeutics, a Seattle, WA-based clinical-stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed-upon deal is subject to customary closing conditions and is fully consistent with Novartis' strategy to focus on innovative medicines. It will significantly expand its renal portfolio, complementing the existing pipeline.

Prurigo Nodularis Treatment Market, By Category

• Product:
• Antihistamines
• Capsaicin Cream
• Corticosteroids
• Emollients
• Others
• Distribution Channel:
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRURIGO NODULARIS TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PRURIGO NODULARIS TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PRURIGO NODULARIS TREATMENT MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Antihistamines
• 5.3 Capsacin Cream
• 5.4 Corticosteroids
• 5.5 Emollients
• 5.6 Others

6 GLOBAL PRURIGO NODULARIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
• 6.2 Retail Pharmacies
• 6.3 Hospital Pharmacies
• 6.4 Online Pharmacies

7 GLOBAL PRURIGO NODULARIS TREATMENT MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL PRURIGO NODULARIS TREATMENT MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Bayer AG
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Galderma SA (Nestle Skin Health Company)
• 9.3 Pfizer, Inc.
• 9.4 Sanofi SA
• 9.5 Takeda Pharmaceutical Company Limited
• 9.6 GlaxoSmithKline Plc
• 9.7 VYNE Therapeutics, Inc.
• 9.8 Trevi Therapeutics, Inc
• 9.9 Merck & Co., Inc.
• 9.10 Novartis AG
• 9.11 Celgene Corporation
• 9.12 Teva Pharmaceutical Industries Ltd.
• 9.13 Johnson & Johnson

10 Appendix

• 10.1 Related Research